Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries G1 Therapeutics Inc (NQ: GTHX ) 2.480 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about G1 Therapeutics Inc < Previous 1 2 3 4 5 Next > New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer May 16, 2023 Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events From G1 Therapeutics Via GlobeNewswire New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC) May 10, 2023 From G1 Therapeutics Via GlobeNewswire Benzinga Pro's Top 5 Stocks To Watch For Tuesday, May 9, 2023: BABA, TSM, LCID, H, GTHX May 09, 2023 Alibaba (BABA) - China's most economically-important companies will be in focus this week ahead of earnings out of the nation's second largest ecommerce company behind Alibaba, JD.com (JD). Via Benzinga Recap: G1 Therapeutics Q1 Earnings May 03, 2023 Via Benzinga Earnings Preview: G1 Therapeutics May 02, 2023 Via Benzinga What 6 Analyst Ratings Have To Say About G1 Therapeutics April 19, 2023 Via Benzinga 7 Analysts Have This to Say About G1 Therapeutics March 02, 2023 Via Benzinga Earnings Scheduled For March 1, 2023 March 01, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. Via Benzinga G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights May 03, 2023 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights March 01, 2023 From G1 Therapeutics Via GlobeNewswire G1 Therapeutics's Earnings Outlook February 28, 2023 Via Benzinga Dow Gains Over 300 Points; S&P 500 Up 1% February 13, 2023 U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 300 points on Monday. The Dow traded up 1.01% to 34,211.29 while the NASDAQ rose 1.52% to 11,896.33. The S&P 500... Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session February 13, 2023 Via Benzinga G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial January 04, 2023 Via Benzinga Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 13, 2023 Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday. Via Benzinga Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet February 13, 2023 U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday. The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500... Via Benzinga Stocks That Hit 52-Week Lows On Monday February 13, 2023 On Monday, 42 companies hit new 52-week lows. Via Benzinga US Stocks Open Higher; Dow Jumps 200 Points February 13, 2023 U.S. stocks traded higher this morning, with the Dow Jones gaining around 200 points on Monday. Following the market opening Monday, the Dow traded up 0.59% to 34,069.23 while the NASDAQ rose 0.65% to... Via Benzinga Why Is Monday.com (MNDY) Stock Up 11% Today? February 13, 2023 Monday.com (MNDY) stock is on the rise Monday after announcing a partnership with Appfire to expand its app marketplace. Via InvestorPlace NVAX Stock Alert: Novavax Will Provide 1.5 Million More Covid-19 Vaccine Doses to U.S. February 13, 2023 Novavax (NVAX) stock is on the move Monday after extending its Covid-19 vaccine supply agreement with the U.S. government. Via InvestorPlace Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today? February 13, 2023 Sorrento Therapeutics (SRNE) stock is falling on Monday after the company filed for bankruptcy alongside Scintilla Pharmaceuticals. Via InvestorPlace Why Is G1 Therapeutics (GTHX) Stock Down 52% Today? February 13, 2023 G1 Therapeutics (GTHX) stock is falling on Monday after the company announced plans to discontinue a Phase 3 clinical trial. Via InvestorPlace 12 Health Care Stocks Moving In Monday's Pre-Market Session February 13, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday February 13, 2023 It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday! Via InvestorPlace G1 Therapeutics Shelves Pivotal Colorectal Trial, After Trilaciclib Triplet Therapy Favored Placebo Arm February 13, 2023 Via Benzinga G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1) February 13, 2023 From G1 Therapeutics Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 January 30, 2023 Via Benzinga G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib January 09, 2023 From G1 Therapeutics Via GlobeNewswire Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment December 07, 2022 From G1 Therapeutics Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 January 05, 2023 Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.